Business context and reporting period
Entity mismatch: The supplied filing is Avista Public Acquisition Corp. II’s Form 10-Q, not a filing identified as Omniab, Inc. It covers the quarter ended September 30, 2021; Avista was a newly formed SPAC and shell company seeking a business combination, not an operating business.
Financial results and position
- Revenue and margins: No operating revenue; the company had not commenced operations. Margins are not meaningful.
- Loss: Net loss was $170,579 for the three months ended September 30, 2021 and $180,550 from inception through September 30. Both reflected formation and operating costs. Quarterly basic and diluted loss per share was $0.01.
- Cash flows: From inception through September 30, operating cash use was $966,382, investing cash use was $235.75 million (funds placed in trust), and financing cash provided was $237.08 million.
- Liquidity: Cash outside the trust was $362,203; working capital surplus was $1.15 million. Trust cash was $235.75 million, or $10.25 per public share.
- Liabilities and equity: Total liabilities were $8.15 million, including an $8.05 million deferred underwriting fee payable only if a business combination closes. Class A shares subject to possible redemption were classified as temporary equity at $235.75 million; shareholders’ deficit was $6.90 million. No debt was reported outstanding at quarter-end.
Material changes and unusual items
The company completed its IPO on August 12, 2021, issuing 23 million units for gross proceeds of $230 million, and sold private placement warrants for $12.35 million. It revised the presentation of redeemable Class A shares to classify all such shares outside permanent equity. The company said the noncash correction was immaterial to its previously issued balance sheet and did not affect cash, expenses, or cash flows.
Outlook, risks, and contingencies
- The company had 18 months from the IPO closing to complete a business combination; otherwise, it must wind up and redeem public shares under the stated terms. Public warrants would expire worthless if no combination is completed.
- Management said outside-trust cash was not expected to fund operations for the next 12 months absent a business combination. The filing states that these conditions raise substantial doubt about the company’s ability to continue as a going concern; management’s plan was to complete a business combination, with no assurance of success or timely completion.
- A forward purchase agreement with the sponsor provides for a potential $100 million purchase of shares and warrants at the business-combination closing, regardless of public-share redemptions.
- Management noted that COVID-19 could adversely affect the company’s financial position or target search, but the impact was not readily determinable. No material changes to previously disclosed risk factors were reported. No legal proceedings or off-balance-sheet arrangements were reported.
Important facts for investors to verify
- Confirm the intended issuer: this filing names Avista Public Acquisition Corp. II, not Omniab, Inc.
- Review the SPAC’s combination deadline, redemption terms, and the risk that warrants may expire worthless.
- Assess the limited operating cash and going-concern disclosure, including the availability and terms of any additional financing.
- Confirm the conditions and funding implications of the $100 million forward purchase agreement and deferred underwriting fee.
- Review the redeemable-share reclassification and related prior-period correction disclosures.